EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression

Michael C B David, Magdalena A Kolanko, Thomas D Parker, Ramin Nilforooshan, Karl A Zimmerman, Cristina Bonet Olivares, Karen Hoang, Johanna Brandt, Charikleia Triantafyllou, Peter J Lally, Gregory Scott, CR&T Group of UKDRI und 2 weitere

Alzheimer's & Dementia · 2025-10 · 21 (10)

DOI: 10.1002/alz.70749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 29.09.2025. Verfasst von Michael C B David und 13 weiteren Autor:innen. Beteiligte Einrichtung: UK Dementia Research Institute Care Research and Technology Centre, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Locus Coeruleus, Substantia Nigra. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the UK DRI, National Institute for Health and Care Research (NIHR) Advanced Fellow, Alzheimer's Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The noradrenergic locus coeruleus (LC) accumulates pathology early in Alzheimer's disease (AD), with LC dysfunction contributing to symptoms and disease progression. We investigated LC and substantia nigra (SN) integrity in healthy controls and AD participants. METHODS Ninety‐three AD participants and 29 controls underwent neuromelanin magnetic resonance imaging. LC and SN contrast, reflecting nucleus integrity, related to cognitive and neuropsychiatric symptoms, as well as cognitive decline and atrophy rates. RESULTS LC – but not SN – integrity was reduced in AD versus controls ( b = −0.39, p = 0.001) and within AD was associated with global cognition ( b = 8.53, p = 0.04) and neuropsychiatric symptoms, accounting for SN. An AD subgroup with reduced SN integrity had worse cognition. LC integrity predicted plasma phosphorylated tau protein 217 ( b = −0.30, p = 0.03). Lower LC and SN integrities were both related to faster cognitive decline (LC: b = −4.74, p = 0.048; SN: b = −2.27, p = 0.03), accounting for one another. DISCUSSION Catecholaminergic nucleus integrity plays an important role in AD. Both systems are relevant to cognitive performance and decline. LC, in particular, relates closely to symptoms, pathology, and rate of progression. Highlights In symptomatic AD, LC integrity reflects cortical AD pathology, measured by pTau217. LC integrity predicts cognitive function in AD, independent of cortical atrophy. LC and SN integrity independently relate to attentional performance. Symptoms of anxiety, depression, and apathy are associated with lower LC integrity. LC and SN relate to cognitive decline rate and left LC predicts atrophy rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseLocus CoeruleusSubstantia NigraHumansFemaleMaleDisease ProgressionAgedMagnetic Resonance ImagingCognitive DysfunctionNeuropsychological TestsAtrophyMelaninstau ProteinsAged, 80 and over

Stichwörter der Autor:innen

catecholaminescognitiondisease progressiondopaminelocus coeruleusneuromelaninneuropsychiatric symptomsnoradrenalinenorepinephrinesubstantia nigra

Substanzen

neuromelaninMelaninstau Proteins

Autor:innen und Institutionen

  • UK Dementia Research Institute Care Research and Technology Centre, Imperial College London, London, UK.
  • Imperial College London, Brain Sciences, South Kensington, London, UK.
  • The Dementia Research Centre, Department of Neurodegenerative Disease, University College London, London, UK.
  • Surrey and Borders Partnership NHS Foundation Trust, Leatherhead, Surrey, UK.

Förderung

  • the UK DRI
  • National Institute for Health and Care Research (NIHR) Advanced Fellow
  • Alzheimer's Society
  • LifeArc
  • Dementias Platform UK
  • Alzheimer's Research UK
  • NIHR Imperial Biomedical Research Centre
  • National Institute for Health and Care Research

Zitieren

APA

David, M. C. B., Kolanko, M. A., Parker, T. D., Nilforooshan, R., Zimmerman, K. A., Bonet Olivares, C., Hoang, K., Brandt, J., Triantafyllou, C., Lally, P. J., Scott, G., CR&T Group of UKDRI, Sharp, D. J., & Malhotra, P. A. (2025). Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70749

Vancouver

David MCB, Kolanko MA, Parker TD, Nilforooshan R, Zimmerman KA, Bonet Olivares C, et al. Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70749

BibTeX
@article{David2025,
  author = {David, Michael C B and Kolanko, Magdalena A and Parker, Thomas D and Nilforooshan, Ramin and Zimmerman, Karl A and Bonet Olivares, Cristina and Hoang, Karen and Brandt, Johanna and Triantafyllou, Charikleia and Lally, Peter J and Scott, Gregory and CR&T Group of UKDRI, CR&T Group of UKDRI and Sharp, David J and Malhotra, Paresh A},
  title = {Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {10},
  doi = {10.1002/alz.70749}
}
Kostenlos starten →